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Abstract
SHP2 protein–tyrosine phosphatase (encoded by Ptpn11) positively regulates KIT (CD117) 
signaling in mast cells and is required for mast cell survival and homeostasis in mice. In this study, 
we uncover a role of SHP2 in promoting chemotaxis of mast cells toward stem cell factor (SCF), 
the ligand for KIT receptor. Using an inducible SHP2 knockout (KO) bone marrow–derived mast 
cell (BMMC) model, we observed defects in SCF-induced cell spreading, polarization, and 
chemotaxis. To address the mechanisms involved, we tested whether SHP2 promotes activation of 
Lyn kinase that was previously shown to promote mast cell chemotaxis. In SHP2 KO BMMCs, 
SCF-induced phosphorylation of the inhibitory C-terminal residue (pY507) was elevated 
compared with control cells, and phosphorylation of activation loop (pY396) was diminished. 
Because Lyn also was detected by substrate trapping assays, these results are consistent with 
SHP2 activating Lyn directly by dephosphorylation of pY507. Further analyses revealed a SHP2- 
and Lyn-dependent pathway leading to phosphorylation of Vav1, Rac activation, and F-actin 
polymerization in SCF-treated BMMCs. Treatment of BMMCs with a SHP2 inhibitor also led to 
impaired chemotaxis, consistent with SHP2 promoting SCF-induced chemotaxis of mast cells via 
a phosphatase-dependent mechanism. Thus, SHP2 inhibitors may be useful to limit SCF/KIT-
induced mast cell recruitment to inflamed tissues or the tumor microenvironment.
Mast cells (MCs) are innate immune cells that serve as sentinels within tissues exposed to 
external environment and release a multitude of mediators that coordinate the immune 
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response (1). However, the aberrant accumulation and activation of MCs also can result in 
progression of some inflammatory disorders (2). MCs also accumulate at the periphery of 
solid tumors and contribute to a microenvironment that facilitates tumor progression and 
metastasis (3). These studies imply that blocking MC recruitment mechanisms in these 
diseases may be an effective way to limit disease progression. Although MCs migrate 
toward distinct chemotactic factors depending on their degree of maturation and 
sensitization to Ags, the stem cell factor (SCF)/KIT signaling axis plays a key role (4). 
Blockade of the SCF/KIT axis has shown promise in limiting MC recruitment and mediator 
release leading to less disease progression (5, 6).
KIT receptor is a receptor tyrosine kinase that promotes crucial MC functions, including 
differentiation, survival, proliferation, migration, and homeostasis (7). KIT also promotes 
homing of MC progenitors to target organs and the differentiation and survival of mature 
MCs within connective tissues. Overexpression of SCF and KIT receptor and elevated MCs 
were detected in the airways of asthma patients (8, 9), and blockade of SCF/KIT improved 
airway function (10, 11). KIT receptor blockade also has improved symptoms in allergic 
rhinitis, scleroderma, and rheumatoid arthritis (5). MCs also are recruited to a variety of 
solid tumors that secrete SCF (12–14), and this triggers MC release of mediators enhancing 
tissue remodeling and immunosuppression. These studies suggest that inhibitors of MC 
chemotaxis and mediator release may improve outcomes in these diseases with MC 
involvement.
Src homology region 2 domain-containing phosphatase 2 (SHP2) is a protein tyrosine 
phosphatase (PTP) that signals downstream of KIT in multiple cell types. Recently, SHP2 
was implicated in KIT signaling pathways leading to survival and homeostasis of 
hematopoietic stem cells (HSCs) (15, 16). In addition, SHP2 also promotes survival of MCs 
via enhancing KIT signaling to ERK and downregulation of Bim (17). The KIT 
juxtamembrane (pY567/pY569) pathway promotes recruitment and activation of SHP2 via 
the Shc/Grb2/Gab2 adaptor proteins, and downstream signaling to the Ras and Rac-JNK 
pathways (18). KIT pY567/pY569 signaling has also been implicated in regulation of cell 
migration through enhancing Lyn kinase activation and calcium mobilization (19). 
However, the contribution of SHP2 to Lyn activation and chemotaxis of MCs has not been 
previously reported. We previously reported that SHP2 knockout (KO) bone marrow–
derived mast cells (BMMCs) fail to repopulate mast cell–deficient mice (17), and these 
defects were more pronounced than the effects on MC survival in vitro. This led us to 
speculate that SHP2 coordinates other aspects of MC homeostasis in vivo, including mast 
cell adhesion and motility.
In this study, we identify a SHP2-dependent pathway promoting MC chemotaxis toward 
SCF using both an inducible SHP2 KO BMMC model (17, 20) and stable silencing of SHP2 
in Baf/3-KIT cells. In both systems, this corresponded to defects in SCF/KIT-induced 
activation of Lyn. Downstream signaling from Lyn also was impaired, including reduced 
phosphorylation of the Rac GEF Vav1 and less active RacGTP at the plasma membrane of 
SHP2 KO BMMCs. This correlated with reduced F-actin polymerization upon SCF 
treatment of SHP2 KO cells. Because SHP2 inhibitor treatment of BMMCs caused similar 
defects in Lyn activation and chemotaxis of BMMCs, this raises the possibility of using 
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SHP2 inhibitors to limit aberrant accumulation of MCs in disease conditions such as 
inflammatory disorders and cancers that secrete SCF.
Materials and Methods
Mice
Transgenic TgCreER:Shp2fl/fl and Shp2fl/fl mice (C57BL/6 background) were described 
previously (1). All animals were housed and bred at Queen’s University Animal Care 
Services, and all procedures were approved by the Queen’s University Animal Care 
committee in accordance with Canadian Council on Animal Care guidelines. Lyn−/− mice 
(C57BL/6 background) (21) were maintained under specific pathogen-free conditions at the 
Indiana University Laboratory Animal Research Center (Indianapolis, IN), and the study 
was approved by the Institutional Animal Care and Use Committee of the Indiana University 
School of Medicine.
Reagents
The following primary Abs were used: mouse anti-Rac1 (Millipore), mouse anti-active Rac 
(NewEast Biosciences), rabbit anti–pY507-Lyn (Epitomics), rabbit anti–pY416-Src (Cell 
Signaling Technology; cross reacts with pY396-Lyn), rabbit anti–pY527-Src (Cell Signaling 
Technology; cross reacts with pY528-Fyn), anti-Fyn (Santa Cruz Biotechnology), rabbit 
anti-Vav1 (C-14; Santa Cruz Biotechnology), rabbit anti-ERK (Santa Cruz Biotechnology), 
mouse anti–β-actin (Santa Cruz Biotechnology), anti-tubulin (Sigma-Aldrich), mouse anti-
pY99 (Santa Cruz Biotechnology), rabbit anti-SHP2 (Santa Cruz Biotechnology), and rabbit 
anti-Lyn (Santa Cruz Biotechnology). Secondary Abs were Alexa Fluor 488–conjugated 
goat anti-mouse IgG (Invitrogen) and Alexa Fluor 568–conjugated goat anti-rabbit IgG 
(Invitrogen). Other reagents included the following: recombinant murine SCF (PeproTech), 
CellTracker Green and CellTracker Orange (Invitrogen), bovine fibronectin (Roche 
Diagnostics), and tetramethylrhodamine isothiocyanate (TRITC)– and Alexa Flour 488–
conjugated phalloidin (Invitrogen).
BMMC cultures
BMMC cultures were established from femoral bone marrow cells as described previously 
(20). In the presence of IL-3–conditioned media, nonadherent cells at 4–6 wk were mature 
MCs based on high expression of KIT and FcεRIα tested by flow cytometry. Mature 
BMMCs from Shp2fl/fl and TgCreER:Shp2fl/fl mice were treated with 4-hydroxytamoxifen 
(4TM; Sigma-Aldrich) for 3 d to obtain wild-type (WT) and KO cultures, respectively. The 
extent of SHP2 inactivation was determined by SHP2 immunoblot and PCR analysis of 
genomic DNA, as described previously (17). Lyn−/− BMMCs were generated from Lyn−/− 
mice as described above and tested for maturity (>95% KIT+/FcεRIα+) prior to experiments 
(WT C57BL/6 mice served as Lyn+/+ control).
SCF treatment and immunoblotting
For SCF stimulation, BMMCs (5 × 106/sample) were starved of IL-3 for 6 h, washed twice 
in Tyrode’s buffer (10 mM HEPES [pH 7.5], 130 mM NaCl, 5 mM KCl, 1.4 mM CaCl2,1 
mM MgCl2, 5.6 nM glucose, and 0.1% BSA), and stimulated with or without SCF (50 
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ng/ml; PeproTech) for 5 or 15 min at 37°C. In case of II-B08 treatment, BMMCs were 
grown in the presence of IL-3/SCF for 3 wk and then treated with either DMSO or different 
concentrations of II-B08 (10–50 μM) for 1 h at 37°C. Lysates were prepared as described 
previously (20). Immunoprecipitations (IPs) were performed with rabbit anti-Vav IgG 
overnight at 4°C, recovered using GammaBind Sepharose (GE Healthcare), and washed 
prior to immunoblotting (IB) with indicated Abs. Signals were revealed by using appropriate 
HRP-conjugated secondary Abs and ECL reagents (Pierce, Thermo Scientific).
Chemotaxis assays
Transwell filters (BD Biosciences) were used to assess chemotaxis of BMMC (3 μm pore) 
or Baf3-KIT (8 μm pore) cells as reported previously (22). Briefly, filters were coated with 
fibronectin (20 μg/ml) overnight at 4°C, and cells starved of IL-3 (4 × 105/well) were plated 
in the upper chamber and allowed to migrate toward media containing SCF (25 ng/ml) in the 
lower chamber for 4 h at 37°C. Nonmigrating cells in the upper chamber were removed with 
a cotton swab prior to fixation of migrating cells with 4% paraformaldehyde and staining 
with DAPI (300 nM). Filters were imaged using an epifluorescence microscope, and images 
were analyzed using ImageJ (National Institutes of Health) to score migrating cells. In case 
of Baf/3-KIT cells, migrating cells within the lower chamber were scored using an 
automated cell counter. Agarose drop chemotaxis assays using SCF-embedded agarose was 
described recently (13). Briefly, SCF (30 ng/ml) was embedded in a drop containing 0.5% 
low-melt agarose and allowed to solidify on dried coverslips previously coated with 
fibronectin (20 μg/ml) and stabilized at 4°C for 15 min. Starved BMMCs (4 × 106; WT or 
KO) were treated with either DMSO or different doses of II-B08 (10–20 μM) and slowly 
added to each for 18–24 h at 37°C. Subsequently, agarose drops were carefully removed, 
and cells on the coverslip were fixed with cold 4% paraformaldehyde, prior to staining with 
DAPI to visualize cell nuclei. To quantify migration of cells under the agarose drop, 
epifluorescence micrographs were acquired using DAPI staining and analyzed using ImageJ 
software. The viability of cells treated with II-B08 or vehicle was assessed using alamar blue 
assays, as described previously (17).
For live cell imaging, WT and KO BMMCs were starved of cytokines, stained with 
CellTracker Orange and Green (Invitrogen; 5 μM), respectively, and mixed at a 1:1 ratio (1 
× 106 total cells). Cells were seeded on coverslips and allowed to migrate for 18 h in a 
climate-controlled chamber mounted on a WaveFX spinning disc confocal microscope (×10 
objective, 21 z-axis slices; Quorum Technologies). Images were acquired every 2 min for 
multiple fields spanning the edge of the agarose drop. Metamorph software was used to 
compile overlay images and videos, whereas the calculation of migration parameters 
(distance, velocity) was performed by tracking individual cells using ImageJ software.
Immunofluorescence
For spreading and polarization assays, starved WT and KO BMMCs were plated on 
fibronectin (20 μg/ml)-coated coverslips in SCF (25 ng/ml) containing media for 45 min. 
Immunofluorescence staining was performed after fixation in cold 4% paraformaldehyde, 
permeabilization in PBS/0.2% Triton X-100, and incubated with anti-active Rac1 Ab (1:75) 
and anti-Lyn Ab (1:50) overnight at 4°C. Active-Rac1, Lyn, and F-actin were detected using 
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TRITC–phalloidin (1:200), Alexa Fluor 488–conjugated goat anti-mouse IgG, and Alexa 
Flour 568–conjugated goat anti-rabbit IgG (1:200) or TRITC–phalloidin alone for 1 h at 
room temperature. After washing three times with PBS, cells on the coverslip were stained 
with DAPI (300 nM) for 10 min at room temperature, followed by mounting coverslips on 
glass slides. Confocal micrographs were acquired using a Leica TCS SP2 Multi Photon 
confocal microscope (HCX PL APO DIC ×63/1.32 Oil CS objective). The quantification of 
cell spreading and polarization was acquired using ImageJ software. Total internal reflective 
fluorescence (TIRF) micrograph was acquired using WaveFX spinning disc confocal 
microscope equipped with TIRF module (Spectral Applied Research). Colocalization 
analysis of active-Rac1 and F-actin channels was performed on overlayed images (n = 20) to 
calculate Mander’s coefficient using colocalization plug-in for ImageJ software.
F-actin polymerization assays
Total F-actin was measured in BMMCs treated with or without SCF as recently described 
(23). Briefly, WT and KO BMMCs were starved of IL-3 for 6 h, resuspended at 106/ml in 
Tyrode’s buffer [10 mM Hepes pH 7.4, 130 mM NaCl, 5 mM KCl, 1.4 mM CaCl2, 1 mM 
MgCl2, 5.6 mM glucose, 0.1% BSA], and treated with SCF (100 ng/ml) for 0–30 min. 
Aliquots (0.5 ml) were removed at indicated times and fixed in cold 4% paraformaldehyde/5 
mM EGTA/5 mM EDTA and permeabilized in PBS/0.1% saponin/2% BSA. Cells were 
stained with 10 nM AlexaFluor-488-conjugated phalloidin for 1 h, rinsed, and analyzed by 
flow cytometry.
Substrate trapping
Baf/3-KIT SHP2 KD2 cells (2 × 108 cells) were stimulated with SCF (50 ng/ml) for 5 min 
and lysed with substrate trapping buffer (20 mM Tris [pH 7.5], 100 mM NaCl, 1% Triton 
X-100, 10% glycerol, 5 mM iodoacetic acid, 1 mM vanadate, 10 μg aprotinin/ml, 10 μg 
leupeptin/ml, and 100 μM phenylmethyl sulfonyl fluoride) to obtain lysates. Excess 
iodoacetic acid was denatured with 10 mM DTT for 15 min at 4°C, prior to incubation with 
GST or a GST fusion to human SHP2 PTP domain [with D425A/Q506A [D/A:Q/A] 
substrate trapping mutations (24)] that were prebound to glutathione Sepharose 4B beads. 
After incubation overnight at 4°C, beads were washed three times with ice-cold substrate 
trapping buffer supplemented with 1 mM EDTA and denatured with SDS-PAGE sample 
buffer and analyzed by IB with indicated Abs.
Baf/3-KIT cells and SHP2 silencing
Baf3-KIT cells were previously reported (19) and were grown in RPMI 1640/10% FBS/2% 
(v/v) IL-3–conditioned media. Baf3-KIT cells were transduced with pGIPZ-based 
lentiviruses expressing nontargeting (NT) or mouse SHP2–specific short hairpin RNAs 
(shRNAs; Invitrogen). Lentiviral packaging, transduction, and titer evaluation was 
accomplished as described previously (2). Single clones of each transduced shRNAs were 
identified and isolated based on sorting of GFP-positive cells by FACS. The most effective 
shRNAs (shRNA1: clone A9 (V3LMM_430009), mature antisense, 5′-
TTATCTGTGGTCTCAGCCA-3′; shRNA2: clone C2 (V2LMM_782273), mature 
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antisense, 5′-ATATTGGTATATTCATGTC-3′) were determined following immunoblot 
analysis and correspond to KD1 and KD2 cell lines, respectively.
Statistical analyses
Differences between control and SHP2 KO or KD cells were analyzed using paired Student t 
test, and statistically significant differences (p < 0.05) are indicated within figures. All 
assays were conducted with experimental and assay replicates included.
Results
SHP2 promotes MC spreading, polarization, and chemotaxis toward SCF
SCF/KIT signaling leads to increased adhesion, spreading, polarization, and motility of MCs 
(25–27). To test the role of SHP2 in these processes, we generated BMMCs from shp2fl/fl 
and TgCre-ER: shp2fl/fl mice, and upon reaching maturity (FceRI+/KIT+ > 95%), we treated 
with 4-TM (200 nM) for 3 d to generate WT and KO MCs, as described previously (17, 20). 
Genomic DNA from WT and KO BMMCs was subjected to PCR analysis of floxed and null 
alleles of Shp2. As expected, null alleles were generated only in KO BMMCs (Fig. 1A), and 
this led to reduced levels of SHP2 protein in KO compared with WT BMMCs (Fig. 1B). We 
and others have previously demonstrated defects in KIT signaling to cell proliferation and 
survival pathways in SHP2 KO BMMCs (17, 28). However, the potential role of SHP2 in 
regulating cytoskeletal reorganization and MC motility has not been reported. To assess this, 
WT and KO BMMCs were allowed to attach and spread on fibronectin-coated coverslips in 
the presence of SCF. At early times (15 min), no differences in BMMC attachment were 
observed between genotypes (data not shown). However, at later times (45 min), the 
majority of WT BMMCs had undergone cell spreading, and this was less frequently 
observed in KO BMMCs (Fig. 1C). Quantification of these cell spreading assays revealed a 
significant difference in WT BMMCs (69 ± 3.7%) compared with KO BMMCs (47 ± 7.4%; 
Fig. 1D). Similar defects in percentage of polarized MCs were observed in KO BMMCs 
compared with WT BMMCs (Fig. 1E). Taken together, these results implicate SHP2 in 
promoting spreading and polarization of MCs induced by SCF/KIT signaling.
Next, we tested whether SHP2 also promotes chemotaxis response to SCF in BMMCs. WT 
and KO BMMCs were placed in Transwell chambers for chemotaxis toward SCF as 
described above. In these assays, we observed 54% reduction in migrating KO BMMCs 
compared with WT (Fig. 2A). Similar defects were observed in Baf3/KIT cells with stable 
SHP2 knockdown (KD) compared with an NT shRNA (Supplemental Fig. 1A, 1B). To 
extend on these findings, we analyzed WT and KO BMMC chemotaxis toward SCF-
embedded agarose drops by time-lapse microscopy, as described previously (13). To 
simultaneously analyze WT and KO BMMCs under identical conditions, WT and KO cells 
were stained with CellTracker Orange (WT) or Green (KO) and mixed briefly prior to 
addition to wells containing fibronectin-coated coverslips containing SCF-embedded 
agarose drops (Fig. 2B). Both WT and KO BMMCs adhered to the coverslips surrounding 
the agarose drops within 30 min, and then, coverslips were mounted in imaging chambers 
(37°C, 5% CO2), and live cell imaging was performed by confocal microscopy for up to 16 
h. We observed increased numbers of WT BMMCs that migrated under the agarose drop 
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compared with KO BMMCs (Fig. 2C, see arrows; Supplemental Video 1). Quantification of 
individual WT and KO cells from multiple fields of view revealed significant defects in both 
total migration distance and cell velocity for SHP2 KO compared with WT BMMCs (Fig. 
2D, 2E). Overall, these results identify SHP2 as a positive regulator of KIT-driven 
chemotaxis of MCs.
Lyn is a substrate of SHP2 downstream of KIT
Previously, KIT juxtamembrane signaling to Src family kinases (SFK) including Lyn and 
Fyn kinases have been shown to enhance chemotaxis of cells toward SCF (19, 25, 29). To 
test whether SHP2 regulates KIT signaling to Lyn and Fyn, we compared levels of 
inhibitory phosphorylation sites in Lyn (pY507) and Fyn (pY528) kinases in NT and SHP2 
KD2 cells treated with SCF. As expected, SCF treatment of Baf/3-KIT NT control cells led 
to rapid dephosphorylation of Lyn at Y507, consistent with Lyn activation downstream of 
KIT (Supplemental Fig. 1C). In contrast, SCF-treated SHP2 KD cells had 2- to 3-fold higher 
levels of pY507-Lyn compared with NT controls (Supplemental Fig. 1C). We also tested 
SCF/KIT signaling to Lyn is affected in SHP2 KO BMMCs. SCF stimulation of WT 
BMMCs led to dephosphorylation of Lyn Y507 within 5 min and returned to baseline levels 
at 15 min (Fig. 3A, 3B). However, significantly higher levels of pY507-Lyn were observed 
in SHP2 KO BMMCs compared with WT (Fig. 3A, 3B). In addition, the SCF-induced 
increase in activation loop phosphorylation of Lyn (pY396) observed in WT BMMCs was 
not detected in SHP2 KO BMMCs (Fig. 3A, 3C). Taken together, these results suggest that 
SHP2 is required for Lyn activation downstream of KIT.
In parallel studies of Fyn, we observed no differences in SCF/KIT-induced 
dephosphorylation of Y528 in Fyn between NT and SHP2 KD2 cells (Supplemental Fig. 1C, 
lower panels). The lack of involvement of SHP2 in Fyn activation is consistent with a recent 
study implicating PTPα in activation of Fyn, but not Lyn, in BMMCs treated with SCF (30).
Although SHP2 is known to promote SFK activation indirectly via dephosphorylating 
recruitment sites for Csk in a variety of growth factor pathways (31), a recent study 
identified pY507-Lyn as a direct substrate of SHP2 in the G-CSF receptor pathway (32). To 
test whether Lyn is a direct substrate of SHP2 in the SCF/KIT pathway, substrate trapping 
assays were conducted on lysates prepared from SCF-treated SHP2 KD Baf/3-KIT cells, 
which are expected to have increased phosphorylation levels of SHP2 substrates. The PTP 
domain of SHP2 with substrate trapping mutations (D/A:Q/A) (24, 33) was expressed and 
purified as a GST fusion (GST-PTPD/A:Q/A) and used along with GST as a negative control 
to conduct pull-down assays in the absence (mock) and presence of SCF-treated cell lysates 
(+ lysate). Both pY507-Lyn and total Lyn were recovered at much higher levels with GST-
PTPD/A:Q/A compared with GST alone (Fig. 3D). Other proteins including the previously 
identified SHP2 substrate p190RhoGAP were not recovered in these assays, likely because 
of lack of phosphorylation in SCF-treated cells (Fig. 3D). Taken together, these results 
identify SHP2 as a key PTP involved in Lyn activation within the SCF/KIT pathway, and 
this likely contributes to defects in chemotaxis of SHP2 KO BMMCs.
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SHP2 and Lyn promote KIT signaling to Vav1 in BMMCs
Vav1 is a highly expressed Rac GEF that is recruited to activated KIT and its GEF activity is 
enhanced via tyrosine phosphorylation in an SFK-dependent manner (30, 34, 35). To test 
whether Lyn activation defects observed in SHP2 KO BMMCs impair downstream signaling 
to Vav1, we compared Vav1 pY in WT and KO BMMCs treated with or without SCF. As 
expected, SCF treatment of WT BMMCs led to increased Vav1 pY, however, this response 
was blunted in SHP2 KO BMMCs (Fig. 4A, 4B). To test whether SHP2 regulates Vav1 pY 
via Lyn activation, we generated Lyn+/+ and Lyn−/− BMMCs (Fig. 4C) and performed 
similar analysis of Vav1 pY upon SCF treatment. We observed a marked reduction in SCF-
induced Vav1 pY in the absence of Lyn (Fig. 4D). Taken together, these results implicating 
SHP2 and Lyn in promoting Vav1 pY may contribute to activation of Rho family GTPases 
involved in MC chemotaxis.
SHP2 promotes Rac1 activation and F-actin polymerization via SCF/KIT axis
To further define the potential defects associated with reduced phosphorylation of Vav in 
KO BMMCs, we measured the levels of active Rac at the plasma membrane of actively 
migrating BMMCs. WT and KO BMMCs were stimulated with SCF to induce adhesion to 
fibronectin-coated coverslips, which promotes translocation of active Rac to membranes 
(36) and the appearance of polarized and motile cells (25). An Ab specific for active 
conformation of Rac1 (Rac1GTP) was used for immunofluorescence staining, and the 
membrane pool was visualized using TIRF microscopy. In WT BMMCs, active Rac was 
readily detected at the cell periphery and was colocalized with Lyn and F-actin (Fig. 5A). In 
contrast, KO BMMCs showed less active Rac at the cell periphery and less colocalization of 
Rac1GTP with F-actin (Fig. 5A, 5B). Because Rac activation leads to increased F-actin 
branching and poly-merization at the leading edge of motile cells (37), we tested whether 
SHP2 KO BMMCs have defects in SCF-induced F-actin polymerization. Using a flow 
cytometry-based assay of SCF-induced changes in F-actin that was previously reported (38), 
WT and KO BMMCs were treated with SCF (0–30 min) prior to permeabilization, staining 
with phalloidin, and analysis by flow cytometry. As expected, SCF treatment of WT 
BMMCs led to a rapid increase in total F-actin levels compared with untreated cells (Fig. 
5C). In contrast, KO BMMCs showed a net loss of F-actin at early times (2–10 min), prior 
to net gains in F-actin at later times that approached the levels of WT BMMCs (Fig. 5C). 
This delay in SCF-induced F-actin polymerization likely contributes to cell spreading and 
motility defects we observed, which are consistent with SHP2 enhancing KIT signaling to a 
Lyn/Vav/Rac pathway in MCs.
SHP2 inhibitor limits chemotaxis of BMMCs toward SCF
To investigate whether SHP2 scaffolding function or phosphatase activity was responsible 
for its role in promoting BMMC chemotaxis toward SCF, we used the recently described 
SHP2 inhibitor II-B08 (17, 39). BMMCs were pretreated with either vehicle (DMSO) or 
increasing doses of II-B08 (10 or 20 μM). Lysates were subjected to IB with anti–phospho-
ERK (pERK), because ERK activation is positively regulated by SHP2 downstream of KIT 
in BMMCs (17). Indeed, less pERK was observed in the presence of II-B08 compared with 
DMSO (Fig. 6A). Likewise, II-B08 treatment led to increased levels of pY507-Lyn in 
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BMMCs (Fig. 6A). At these doses of II-B08, only a moderate reduction in cell viability was 
observed in BMMCs (Fig. 6B; not statistically significant).
Next, we tested whether SHP2 inhibitor can mimic the effects of gene KO in SCF-induced 
chemotaxis assays. BMMCs were treated with either DMSO or II-B08 (10 or 20 μM) and 
analyzed using the agarose drop chemotaxis assay. We observed no effects of II-B08 
treatment on the ability of BMMCs to adhere to coverslips surrounding the SCF-embedded 
agarose drop; however, fewer cells migrated underneath the drop in cells treated with 20 μM 
II-B08 (Fig. 6C, 6D). Taken together, these results implicate SHP2 phosphatase activity in 
promoting Lyn activation and downstream signaling pathway, which drives chemotaxis of 
MCs (Fig. 6E).
Discussion
SHP2 is a key mediator of SCF/KIT signaling that enhances MC proliferation and survival 
pathways (17, 18). Although SHP2 modulates these key facets of KIT signaling in vitro, the 
magnitude of these defects was unlikely to fully explain the severe defect in MC 
homeostasis we observed in MC-specific SHP2 KO mice (17). We hypothesized that SHP2 
also may promote aspects of MC homing and motility within connective tissues. SCF is a 
potent chemoattractant of MCs both in vitro and in vivo, and localized SCF production leads 
to MC accumulation at sites of inflammation and tumorigenesis (5, 6). In this study, we 
report that SHP2 is a positive regulator of MC chemotaxis toward SCF using genetic and 
pharmacological approaches. Using both SHP2 gene silencing in Baf/3-KIT cells and SHP2 
KO BMMCs, we observed reduced chemotaxis toward SCF. KIT juxtamembrane signaling 
to SFKs was previously implicated in chemotaxis toward SCF (19). Because SHP2 enhances 
SFK activation in several growth factor pathways (31), we tested its effects on Lyn and Fyn 
kinases that both contribute to MC chemotaxis (25, 29). In both Baf/3-KIT and BMMCs 
models, SHP2 was found to promote dephosphorylation of inhibitory Y507 in Lyn upon 
SCF treatment. In contrast, Fyn kinase dephosphorylation downstream of KIT was 
independent of SHP2 and is consistent with PTPα being responsible for Fyn but not Lyn 
activation downstream of KIT (30). Further analysis by substrate trapping identified Lyn as 
a direct substrate of SHP2 in SCF-treated cells. This is consistent with another recent study 
implicating SHP2 in dephosphorylating Lyn pY507 to promote Lyn activation downstream 
of G-CSF receptor (32). The coordination of SHP2 and Lyn signaling downstream of KIT 
(Fig. 6E) is consistent with both proteins being required for optimal chemo-taxis of MCs 
toward SCF (29).
Rac GTPases play key roles in SCF/KIT signaling to gene expression and cytoskeletal 
regulation in MCs (40). KIT signaling to Rac GEFs and GAPs leads to temporal and spatial 
control of a pool of active Rac (RacGTP) that signals to downstream effectors in MCs. 
Although a previous study identified SHP2 as a positive regulator of KIT signaling to Rac 
(28), the signaling mechanism remained unclear. In this study, we extend on these analyses 
to show that SHP2 enhances the plasma membrane pool of RacGTP in SCF-treated BMMCs 
undergoing cell spreading and polarization. This finding suggests that SHP2 either promotes 
activation of Rac GEFs or inhibition of a Rac GAPs. Previous studies implicate SFKs in 
promoting Rac activation and tyrosine phosphorylation of the Rac GEF Vav (25, 30, 41). 
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Consistent with reduced Lyn activation in SCF-treated SHP2 KO BMMCs, we also 
observed less Vav1 pY in these cells compared with WT BMMCs. This is consistent with a 
KIT/SHP2/Lyn/Vav1/Rac pathway to regulate chemotaxis of MCs (Fig. 6E). SHP2 also may 
regulate chemotaxis via Rho GAPs. For example, β2-chimaerin is a Rac GAP and SFK 
substrate implicated in breast cancer progression that would be worth testing in future 
studies (42). Rac effectors include key regulators of F-actin polymerization and branching, 
such as the PAK/Cortactin/Arp2/3 and WAVE/Scar/Arp2/3 complexes (43). Our findings 
that SHP2 KO BMMCs show delayed F-actin polymerization upon SCF treatment is 
consistent with the observed defects in signaling and RacGTP at the plasma membrane. This 
is expected to contribute to the defects in cell spreading and motility we observed in SHP2-
deficient MCs.
A number of studies highlighted the role of KIT receptor and its downstream effector 
including SFKs, PI3K, and Gab2 in MC migration. In this study, we report that SHP2 
promotes both the intrinsic velocity and persistence of MC chemotaxis toward SCF, as 
measured by live cell imaging. Importantly, these agarose drop assays allowed us to 
simultaneously visualize chemotaxis of WT and KO BMMCs and provided additional 
evidence for direct regulation of motility by SHP2. The additional testing of SHP2 inhibitor 
II-B08 in BMMC chemotaxis toward SCF revealed that SHP2 PTP activity is largely 
responsible for its promigratory role. This is consistent with SHP2 recruitment and 
activation to KIT-Grb2-Gab2 complexes following MC exposure to SCF (28), and this 
likely colocalizes active SHP2 with inhibited pool of Lyn (pY507-Lyn) at the plasma 
membrane. Subsequent dephosphorylation of Lyn leads to phosphorylation of downstream 
substrates such as Vav and Rac signaling to actin regulatory proteins that promote 
cytoskeletal reorganization and motility. It is certainly possible that SHP2 silencing or KO 
also impairs signaling that requires SHP2 scaffolding functions, as reported in for signaling 
by LEOPARD syndrome mutations in SHP2 (44, 45). Future studies will be required to 
directly test the relative effects of genetic and pharmacological blockade of SHP2 function 
in MCs in vitro and in vivo. Of particular interest would be testing SHP2 inhibitors in cancer 
models, whereby SHP2 inhibition within both tumor cells and stromal MCs might lead to 
reduced tumor progression. Recently, both genetic and pharmacological approaches to 
inhibit SHP2 resulted in reduced KITD814V-driven myeloproliferative disease in mice and 
identified SHP2 as a druggable target (46). Future studies also will be required to test the 
effects of SHP2 inhibitors on recruitment of MCs to the tumor microenvironment, and 
whether this limits tumor progression to meta-static disease. SHP2 inhibitors also may 
reduce accumulation of MCs at sites of allergic inflammation and could be tested in these 
disease models as well.
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Abbreviations used in this article
BMMC bone marrow–derived mast cell
DRM detergent-resistant membrane
HSC hematopoietic stem cell
IB immunoblotting
IP immunoprecipitation
KD knockdown
KO knockout
MC mast cell
NT non-targeting
PTP protein-tyrosine phosphatase
SCF stem cell factor
SFK Src family kinase
SHP2 SH2 domain-containing phosphatase-2
shRNA short hairpin RNA
TIRF total internal reflective fluorescence
4TM 4-hydroxytamoxifen
TRITC tetramethylrhodamine isothiocyanate
WT wild-type
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FIGURE 1. 
Defective cell spreading and polarization in SHP2 KO BMMCs treated with SCF. (A) 
BMMCs obtained from Shp2fl/fl and TgCreER:Shp2fl/fl were treated with 4-TM (200 nM) for 
3 d to generate WT and KO BMMCs, respectively. (A) PCR analyses of Shp2 null and flox 
alleles for genomic DNA isolated from WT and KO BMMCs. Position of DNA size markers 
(kilobases) are shown on the left. (B) IB analysis for WT and KO BMMC lysates probed 
with SHP2 and ERK Abs. Positions of relative mass markers (kDa) are shown on the left. 
(C) WT and KO BMMCs were straved of IL-3 for 6 h and seeded on fibronectin-coated 
coverslips in the presence of SCF (25 ng/ml for 45 min). Cells were fixed, permeabilized, 
and stained with TRITC–phalloidin. Representative epiflourescence micrographs are shown 
for F-actin staining. (D) The graph depicts the percentage of cells that had spread for 
multiple fields for WT and KO BMMCs (n = 4 > 200 cells; mean ± SD; triplicate samples; 
*p < 0.05, significant difference between genotypes. (E) Graph depicts the percentage of 
cells that had polarized for multiple fields for WT and KO BMMCs (n = 4, >200 cells; mean 
± SD; triplicate samples; *p < 0.05, significant difference between genotypes.
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FIGURE 2. 
SHP2 promotes chemotaxis of BMMCs. (A) Transwell assays were performed to measure 
WT and KO BMMC chemotaxis toward SCF (25 ng/ml). The graph depicts the number of 
cells per field (mean ± SD, n = 3 replicates, triplicate samples; *p < 0.05, significant 
difference between genotypes). (B) Schematic representation of experimental design using 
live cell imaging of agarose drop assays. WT and KO BMMCs were stained with 
CellTracker Orange and Green, respectively, and mixed prior to subjecting to SCF-
embedded agarose drop chemotaxis assay, as described in Materials and Methods. (C) 
Representative confocal micrographs showing the positions of WT and KO BMMCs at the 
indicated times (0–16 h) during the time lapse are shown (margin of agarose drop indicated 
by dashed white line). White and yellow arrows depict positions of WT and KO BMMCs, 
respectively, that had migrated under the agarose at 16 h. (D) Cells from multiple fields (n = 
5, >30 cells/genotype) were tracked individually to calculate migration distances 
(micrometers). The graph depicts mean migration distance (± SD) for WT and KO BMMCs 
(*p < 0.05, significant difference between genotypes). (E) Graph depicts the average 
velocity (micrometer per minute) for the same set of WT and KO BMMCs described in (D) 
(*p < 0.05, significant difference between genotypes).
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FIGURE 3. 
Lyn C-terminal inhibitory tyrosine residue (pY507) is a direct substrate of SHP2. (A) WT 
and KO BMMCs were starved of IL-3 for 6 h and stimulated with SCF (50 ng/ml) for 
indicated times. Lysates were subjected to IB analysis with pY507-Lyn, pYSrc 416 (cross-
reacts with pY396 Lyn) and Lyn Abs. (B and C) Line graph depicting the relative 
phosphotyrosine levels of Lyn at tyrosines 507 and 396, respectively, at indicated time 
points (mean ± SD; n = 3; *p < 0.05, significant difference between genotypes). (D) Lysates 
were prepared from SCF-treated Baf/3-KIT SHP2 KD cells (50 ng/ml for 5 min) and 
incubated with either GST or GST-PTPD/A:Q/A bound to beads overnight at 4°C. Mock 
reactions were performed with including lysates. IB analyses were carried out with Abs 
indicated on the right.
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FIGURE 4. 
SHP2 and Lyn promote phosphorylation of Vav1 downstream of KIT. (A) Lysates prepared 
from WT and KO BMMCs were subjected to IP with anti-Vav1 prior to IB analysis using 
anti-pY (PY99) and anti-Vav1. Positions of relative mass markers (kilodaltons) are shown 
on the left. (B) Graph depicting the relative total phosphotyrosine levels of Vav1 at indicated 
time points (mean ± SD; n = 4; *p < 0.05, significant difference between genotypes). (C) 
Lysates prepared from Lyn+/+ and Lyn−/− BMMCs were subjected to IB analysis with anti-
Lyn and anti-actin. (D) Lysates prepared from Lyn+/+ and Lyn−/− BMMCs were subjected 
IP with anti-Vav1 prior to IB analysis using anti-pY (PY99) and anti-Vav1. Positions of 
relative mass markers (kilodaltons) are shown on the left.
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FIGURE 5. 
Reduced plasma membrane RacGTP and F-actin polymerization in SHP2 KO BMMCs 
treated with SCF. (A) WT and KO BMMCs were starved of IL-3 for 6 h and plated on 
fibronectin-coated coverslips in presence of SCF (25 ng/ml for 45 min). Fixed and 
permeabilized cells were subjected to immunofluorescence staining with anti-active Rac1 
(Rac1GTP conformation specific) and anti-Lyn. The TIRF micrograph depicting the ventral 
surface of the cells staining membrane fraction of active Rac1 and Lyn and the merge image 
of active Rac1 and Lyn channel. (B) Graph depicting the quantification analysis Mander’s 
coefficient to measure the degree of colocalization of active Rac1 and Lyn channels between 
WT and KO genotypes. (mean ± SD; n = 20; *p < 0.05, significant difference between 
genotypes). (C) Cytokine starved WT and KO BMMCs were stimulated with SCF (100 
ng/ml) for indicated times, fixed, and permeablized prior to staining with Alexa Fluor 488–
conjugated phalloidin. The graph depicts the percentage change in F-actin mean 
fluorescence intensity (mean ± SD; triplicate samples) for WT and KO BMMCs compared 
with 0 min (*p < 0.05, significant difference between genotypes).
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FIGURE 6. 
SHP2 phosphatase activity promotes chemotaxis of BMMCs toward SCF. (A) BMMCs 
grown in IL-3 and SCF for 3 wk were pretreated with vehicle (DMSO) or different 
concentrations of SHP2 inhibitor (II-B08; 10 or 20 μM) for 1 h. Lysates were subjected to 
IB analysis with anti-pERK, anti–phospho-Lyn (pY507), ERK, and Lyn Abs. (B) BMMCs 
grown in IL-3 and SCF for 3 wk were pretreated with DMSO or different concentrations of 
II-B08 as above for 24 h. The graph depicting the percent cell viability determined with 
alamar blue assay as described in Materials and Methods (mean ± SD; triplicate samples). 
(C) Cytokine-starved BMMCs were pretreated for 1 h and maintained with either vehicle 
(DMSO) or different concentrations of SHP2 inhibitor (II-B08; 10 or 20 μM) prior to plating 
on fibronectin-coated coverslips containing SCF-embedded agarose drops. After 18 h, cells 
were fixed and stained with DAPI, and the images were acquired on an epifluorescence 
microscope. Representative micrographs are shown for DAPI+ cells at the margin of the 
agarose drop (dashed line) and underneath the agarose drop (below the dashed line). (D) The 
graph depicting the total number of BMMCs that had migrated under each SCF-embedded 
agarose drop (n = 3 replicates, triplicate samples; **p < 0.01, statistical significant 
difference between the genotype). (E) Simplified pathway model relating SHP2 to mast cell 
chemotaxis. SHP2 promotes Lyn activation downstream of KIT, leading to Vav1 
phosphorylation, Rac activation, and F-actin branching and polymerization required for 
chemotaxis.
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